Radboudumc

Radboud university medical center

Researchers of the Radboud university medical center (Radboudumc) focus on today’s scientific health challenges as well as keeping an eye on emerging diseases of the future. With the mission ‘to have a significant impact on healthcare’ and a strategic focus on personalized healthcare through ‘the patient as partner’, the core activities of patient health care, research and education are bundled in 17 disease-oriented research themes in which fundamental researchers and clinicians meet regularly and integrate their knowledge and expertise to realize important improvements in patient-directed science, diagnosis and treatment. The disease-oriented research themes include cancer development, rare cancers, digestive tract, urological and women’s cancers, infectious, inflammatory, mitochondrial and alzheimer’s diseases, renal, sensory, neurodevelopment and stress-related disorders, and vascular damage. Radboudumc consists of 11.000 colleagues, 50 departments, 3000 students and 1000 beds.

Website

https://www.radboudumc.nl/en/research

Contact

Hans van Bokhoven
hans.vanbokhoven@radboudumc.nl 

Silvia Albert
Silvia.Albert@radboudumc.nl

Added value for hDMT

Added value for Radboudumc

 

Radboudumc expertise and facilities

 

Expertise relevant for Organ-on-Chip technology:

 

Facilities relevant for Organ-on-Chip technology:

Embedding Organ-on-Chip technology in research policy


For many themes, the Organ-on-Chip technology forms the interphase between molecular studies and physiological studies in patients. Therefore, the Stem Cell and Differentiation Technology Center has been set up and is sponsored by the department of Human Genetics and Radboudumc. In the human movement theme, all projects involve the use of Brain on Chip technology in which neuronal networks of individual patients are phenotyped with the ultimate aim to perform drug screening for individual patients rather that disease specific, i.e. getting to personalized medicine. To increase Organ-on-Chip research and collaboration with the UTwente, the Radboudumc and UTwente provided 4 collaborative TURBO grants.

 

Relevant (inter)national collaborations


Public sector: Prof. Huck (Nijmegen); Profs. M. Verhaar, H. Clevers (Utrecht); Prof. D. Stamatialis, A. van der Meer, Severine le Gac (TU Twente); Pijnappel (Erasmus MC); Rabelink (LUMC); Prof. Davies (Edinburgh); Prof. Eiges (Jerusalem, Israel).
Patient organisations: K.I.D.S. IQ Project (Canada), Koolen-de Vries syndrome foundation (US), Epilepsie Vereniging Nederland.
Private sector: Roche.

 

Relevant grants


- A novel generation of skin substitutes to clinically treat a broad spectrum of severe skin defects. 2011-2017 EU FP7 Health 5996. 9 European partners. 6000 kEuro
- Brain on a dish: development of innovative stem cell technologies for personalized medicine in epilepsy. NWO ZonMW Top PI: H. van Bokhoven, N. Nadif Kasri (Radboudumc), Judith  Verhoeven, Jurgen Schelhaas (Kempenhaeghe Heeze), 675 kEuro.
- EYE-RISK; Exploring the combined roles of genetic and non-genetic factors for developing agerelated macular degeneration: A systems level analysis of disease subgroups, risk factors, and pathways. European Union. Coordinators: M. Ueffing & C. Klaver, 2015-2019, 5.972 kEuro.

Relevant key publications